Reply to “Loganin: A potential pharmacological agent for myocardial ischemia-reperfusion injury”

Our recent work published in the International Journal of Cardiology suggests that loganin treatment inhibits oxidative stress and cellular apoptosis in myocardial ischemia-reperfusion injury (MIRI) in part via Janus kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) [1]. We greatly appreciate the comments of Li et al. suggesting that the anti-inflammatory property of loganin may also explain its protective effect against MIRI. We agree with this view, because our follow-up experiments showed that loganin significantly altered the expression of interleukin-10 (IL-10) in the ischemic area of the left ventricle in mice that received an ischemia-reperfusion stimulus.

Source: International Journal of Cardiology - January 6, 2024 Category: Cardiology Authors: Boyu Xia, Jiaqi Ding, Qi Li, Koulong Zheng, Jingjing Wu, Chao Huang, Kun Liu, Qingsheng You, Xiaomei Yuan Tags: Letter to the Editor Source Type: research